Literature DB >> 8199559

Fanconi anemia revisited: old ideas and new advances.

C C dos Santos1, H Gavish, M Buchwald.   

Abstract

This review summarizes both historical and more recent data on the clinical, cellular and genetic features of Fanconi anemia (FA), a rare autosomal recessive disorder. FA patients are characterized by pancytopenia, congenital malformations, growth delay and an increased susceptibility to the development of malignancies, particularly acute myelogenous leukemia. FA cells show chromosomal fragility, slow growth and increased sensitivity to DNA crosslinking agents. FA can be caused by defects in any one of at least four genes. Two general hypotheses have been proposed to explain the underlying defect: loss of a DNA repair function or of a step in the defense toward oxygen toxicity. After many attempts to clone the FA genes, the first one, that defective in group C, has been cloned by complementation of the increased sensitivity of FA(C) cells to mitomycin C and diepoxybutane. This gene (FACC) codes for a novel protein and is ubiquitously expressed. Mutations in various FA(C) patients that cause loss of function have been identified. The review concludes by suggesting directions for future research in FA.

Entities:  

Mesh:

Year:  1994        PMID: 8199559     DOI: 10.1002/stem.5530120202

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  3 in total

1.  Body proportions in Fanconi anemia heterozygotes.

Authors:  S Mohan; P Lakshminarayanan; P Sowmya; M Venkatadesikalu; V Pushpa
Journal:  Indian J Pediatr       Date:  2000-11       Impact factor: 1.967

2.  A Rad50-dependent pathway of DNA repair is deficient in Fanconi anemia fibroblasts.

Authors:  Sarah L Donahue; Colin Campbell
Journal:  Nucleic Acids Res       Date:  2004-06-15       Impact factor: 16.971

3.  Fanconi anemia manifesting as a squamous cell carcinoma of the hard palate: a case report.

Authors:  Giulio Gasparini; Gianluigi Longobardi; Roberto Boniello; Alessandro Di Petrillo; Sandro Pelo
Journal:  Head Face Med       Date:  2006-01-13       Impact factor: 2.151

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.